Sarepta Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Sarepta Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Sarepta Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $33.6M.
  • Sarepta Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $122M.
  • Sarepta Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$536M, a 23.8% increase from 2022.
  • Sarepta Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$703M, a 68% decline from 2021.
  • Sarepta Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$419M, a 24.4% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $122M $33.6M +$74.5M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $47.3M $6.46M +$30.4M Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 $16.9M $36.1M +$553M Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 -$536M $45.7M +$155M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$691M -$40.9M +$217M +84.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$908M -$23.9M +$208M +89.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$1.12B -$517M -$412M -392% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$703M -$109M +$12.7M +10.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$716M -$258M -$210M -435% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$507M -$231M -$150M -184% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$357M -$105M +$62.2M +37.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
Q4 2021 -$419M -$122M +$67.3M +35.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$486M -$48.1M +$148M +75.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$634M -$81.4M +$69.4M +46% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-02
Q1 2021 -$704M -$167M -$150M -856% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-02
Q4 2020 -$554M -$189M +$46.4M +19.7% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$601M -$196M -$70.2M -55.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$530M -$151M +$126M +45.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-03
Q1 2020 -$656M -$17.5M +$59.2M +77.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-03
Q4 2019 -$715M -$236M -$94.8M -67.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$620M -$126M -$49.9M -65.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$570M -$276M -$167M -153% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$403M -$76.6M -$41.3M -117% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$362M -$141M -$117M -487% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 -$245M -$76.4M -$28.7M -60% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 -$216M -$109M -$46.2M -73.3% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$170M -$35.4M -$119M -142% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$50.7M -$24M +$64.5M +72.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$115M -$47.7M +$9.01M +15.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$124M -$63M -$745K -1.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$123M $84.1M +$144M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$267M -$88.5M -$23.8M -36.8% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$243M -$56.7M -$4.8M -9.25% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$239M -$62.3M -$20.5M -48.9% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$218M -$59.8M +$1.79M +2.91% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$220M -$64.7M -$20.3M -45.6% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-28
Q3 2015 -$200M -$51.9M -$22.7M -77.7% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-28
Q2 2015 -$177M -$41.9M -$7.98M -23.5% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-28
Q1 2015 -$169M -$61.6M -$33.3M -118% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-28
Q4 2014 -$136M -$44.4M -$35.6M -404% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-25
Q3 2014 -$100M -$29.2M +$12.8M +30.5% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-25
Q2 2014 -$113M -$33.9M -$14.8M -77.8% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-25
Q1 2014 -$98.2M -$28.3M +$13.8M +32.8% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-25
Q4 2013 -$112M -$8.82M +$53.2M +85.8% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-26
Q3 2013 -$165M -$42M +$7.52M +15.2% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-26
Q2 2013 -$173M -$19.1M -$27.1M -337% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-26
Q1 2013 -$146M -$42.1M -$24.4M -138% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-26
Q4 2012 -$121M -$62.1M -$60.7M -4302% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-03
Q3 2012 -$60.6M -$49.6M -$45.5M -1133% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-03
Q2 2012 -$15.1M $8.04M +$6.76M +528% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-03
Q1 2012 -$21.9M -$17.7M -$19.5M -1066% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-03
Q4 2011 -$2.32M -$1.41M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-15
Q3 2011 -$4.02M +$3.27M +44.9% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-15
Q2 2011 $1.28M +$17.9M Apr 1, 2011 Jun 30, 2011 10-K 2013-03-15
Q1 2011 $1.83M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-15
Q3 2010 -$7.29M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$16.7M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.